GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valiant Laboratories Ltd (BOM:543998) » Definitions » EPS (Diluted)

Valiant Laboratories (BOM:543998) EPS (Diluted) : ₹-0.51 (TTM As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Valiant Laboratories EPS (Diluted)?

Valiant Laboratories's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was ₹0.16. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-0.51.

Valiant Laboratories's EPS (Basic) for the three months ended in Mar. 2025 was ₹0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-0.51.

Valiant Laboratories's EPS without NRI for the three months ended in Mar. 2025 was ₹0.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-0.51.

During the past 12 months, Valiant Laboratories's average EPS without NRIGrowth Rate was -492.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Valiant Laboratories's highest 3-Year average EPS without NRI Growth Rate was -73.60% per year. The lowest was -73.60% per year. And the median was -73.60% per year.


Valiant Laboratories EPS (Diluted) Historical Data

The historical data trend for Valiant Laboratories's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valiant Laboratories EPS (Diluted) Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
EPS (Diluted)
7.04 6.33 6.67 0.13 -0.51

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.12 -1.09 0.54 0.16

Competitive Comparison of Valiant Laboratories's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valiant Laboratories's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's PE Ratio distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's PE Ratio falls into.


;
;

Valiant Laboratories EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Valiant Laboratories's Diluted EPS for the fiscal year that ended in Mar. 2025 is calculated as

Diluted EPS (A: Mar. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-22.012-0)/43.161
=-0.51

Valiant Laboratories's Diluted EPS for the quarter that ended in Mar. 2025 is calculated as

Diluted EPS (Q: Mar. 2025 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(7.039-0)/42.564
=0.17

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valiant Laboratories  (BOM:543998) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Valiant Laboratories EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Valiant Laboratories's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Valiant Laboratories Business Description

Traded in Other Exchanges
Address
Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.

Valiant Laboratories Headlines

No Headlines